BIOVENTUS INC - A (BVS) Stock Analyst Ratings
NASDAQ:BVS • US09075A1088
8.86 USD
+0.11 (+1.26%)
At close: Feb 26, 2026
8.86 USD
0 (0%)
After Hours: 2/26/2026, 8:13:33 PM
ChartMill assigns a Buy % Consensus number of 80% to BVS. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 15.3. This target is 72.69% above the current price.
- BVS was analyzed by 7 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about BVS.
- In the previous month the buy percentage consensus was at a similar level.
- BVS was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-09 | Barrington Research | Initiate | Outperform |
| 2025-07-07 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-03-17 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-12-17 | JP Morgan | Upgrade | Underweight -> Neutral |
| 2024-11-06 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-09-27 | Craig-Hallum | Maintains | Buy -> Buy |
| 2024-08-13 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-08-07 | Craig-Hallum | Maintains | Buy -> Buy |
| 2024-05-08 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-03-13 | Craig-Hallum | Maintains | Buy -> Buy |
| 2023-12-07 | Canaccord Genuity | Upgrade | Hold -> Buy |
| 2023-04-03 | Craig-Hallum | Maintains | Hold |
| 2022-11-30 | Goldman Sachs | Maintains | Neutral |
| 2022-11-22 | Craig-Hallum | Downgrade | Buy -> Hold |
| 2022-11-10 | Morgan Stanley | Maintains | Overweight |
| 2022-11-09 | JP Morgan | Downgrade | Overweight -> Underweight |
| 2022-11-09 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2022-10-11 | Morgan Stanley | Maintains | Overweight |
| 2022-09-07 | Goldman Sachs | Maintains | Neutral |
| 2022-08-12 | Morgan Stanley | Maintains | Overweight |
| 2022-05-12 | Morgan Stanley | Maintains | Overweight |
| 2022-03-11 | Morgan Stanley | Maintains | Overweight |
| 2021-11-15 | Morgan Stanley | Reiterate | Overweight |
| 2021-07-01 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2021-04-19 | Morgan Stanley | Maintains | Overweight |
| 2021-03-08 | JP Morgan | Initiate | Overweight |
| 2021-03-08 | Canaccord Genuity | Initiate | Buy |
| 2021-03-08 | Goldman Sachs | Initiate | Buy |
| 2021-03-08 | Morgan Stanley | Initiate | Overweight |
BIOVENTUS INC - A / BVS FAQ
Can you provide the average price target for BIOVENTUS INC - A stock?
7 analysts have analysed BVS and the average price target is 15.3 USD. This implies a price increase of 72.69% is expected in the next year compared to the current price of 8.86.
Can you provide the consensus rating for BIOVENTUS INC - A stock?
The consensus rating for BIOVENTUS INC - A (BVS) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover BIOVENTUS INC - A (BVS) stock?
The number of analysts covering BIOVENTUS INC - A (BVS) is 7.